Cantor Fitzgerald Maintains Overweight on Exagen, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Ross Osborn maintains an Overweight rating on Exagen (NASDAQ:XGN) and raises the price target from $5 to $7.
May 14, 2024 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald's analyst Ross Osborn reaffirmed an Overweight rating on Exagen and increased the price target from $5 to $7, indicating a positive outlook on the company's stock.
The upgrade in price target by a reputable analyst like Ross Osborn suggests a strong confidence in Exagen's future performance. Such endorsements typically lead to a positive short-term impact on the stock's price as it reassures investors of the company's potential for growth and profitability.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100